GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
== References == Brendon, Piers (2010). The Decline and Fall of the British Empire, 1781–1997 (1st Vintage books ed.). New York City: Vintage Books. ISBN 9780307388414. Cilliers, Jakkie (1985). Counter-Insurgency in Rhodesia (PDF). Beckenham, United Kingdom: Croom Helm. ISBN 0-7099-3412-2. Cline, Lawrence E. (2005). "Pseudo Operations and Counterinsurgency: Lessons from Other Countries" (PDF). Strategic Studies Institute, US Army War College. Cross, G. (2017). Dirty War: Rhodesia and Chemical Biological Warfare, 1975–1980. Helion & Company. ISBN 978-1-911512-12-7. Dzimbanhete, Jephias Andrew (March 2017). "Reverberations of Rhodesian Propaganda in Narratives of Zimbabwe's Liberation War". Journal of Pan African Studies. 10 (1): 295–307. Evans, Michael (June 2007). "The Wretched of the Empire: Politics, Ideology and Counterinsurgency in Rhodesia, 1965–80". Small Wars & Insurgencies. 18 (2): 175–195. doi:10.1080/09574040701400601. S2CID 144153887. Gatchel, Theodore L. (2008). "Pseudo Operations – A Double Edged Sword of Counterinsurgency". In Norwitz, Jeffery H. (ed.). Armed Groups: Studies in National Security, Counterterrorism, and Counterinsurgency. Newport, Rhode Island: US Naval War College. pp. 61–74. ISBN 9781884733529. Martinez, Ian (December 2002). "The History of the Use of Bacteriological and Chemical Agents during Zimbabwe's Liberation War of 1965–80 by Rhodesian Forces". Third World Quarterly. 23 (6): 1159–1179. doi:10.1080/0143659022000036595. ISSN 0143-6597. JSTOR 3993569. S2CID 145729695. McLaughlin, Peter (August 1991).
Historically, brown meal was what remained after about 90% of the coarse, outer bran and 74% of pure endosperm or fine flour was removed from the whole grain. Using slightly different extraction numbers, brown meal, representing 20% of the whole grain, was itself composed of about 15% fine bran and 85% white flour. In 1848 it was asserted grain millers knew only of bran and endosperm, but by 1912 it was more widely known that brown meal included the germ.
== Prescription labels == Medication packaging includes a document that provides information about that drug and its use. In the US, this information is overseen by the Center for Drug Research and Evaluation (CDER), a branch of the Food and Drug Administration (FDA). For prescription medications, the insert is technical, and provides information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user -- the person who will take the drug or administer the drug to another person. Inserts for over-the-counter medications are also written plainly. In the US the document is called "prescribing information" or the "package insert" (PI) and layperson's document is called the "patient package insert" (PPI). In Europe the technical document is called the "summary of product characteristics" and the document for end-users is called the "package leaflet". The bottle or box also has information printed on it, intended for the person taking the medication.
== History == The term "fine chemicals" was in use as early as 1908. The emergence of the fine chemical industry as a distinct entity dates to the late 1970s, when the overwhelming success of the histamine H2 receptor antagonists Tagamet (cimetidine) and Zantac (ranitidine hydrochloride) created a strong demand for advanced organic chemicals used in their manufacture. As the in-house production capacities of the originators, the pharmaceutical companies Smith, Kline, & French and Glaxo, could not keep pace with the rapidly increasing requirements, both companies (now merged as GlaxoSmithKline) outsourced part of the manufacturing to chemical companies experienced in producing relatively sophisticated organic molecules. Lonza, Switzerland, which had already had supplied an early intermediate, methyl acetoacetate, during drug development, soon became the main supplier of more and more advanced precursors. The signature of a first, simple supply contract is generally acknowledged as the historical document marking the beginning of the fine chemical industry.
== Withdrawal == Withdrawal symptoms may occur during gradual or particularly abrupt withdrawal of tricyclic antidepressant drugs. Possible symptoms include: nausea, vomiting, abdominal pain, diarrhea, insomnia, headache, nervousness, anxiety, dizziness and worsening of psychiatric status. Differentiating between the return of the original psychiatric disorder and clomipramine withdrawal symptoms is important. Clomipramine withdrawal can be severe. Withdrawal symptoms can also occur in neonates when clomipramine is used during pregnancy. A major mechanism of withdrawal from tricyclic antidepressants is believed to be due to a rebound effect of excessive cholinergic activity due to neuroadaptations as a result of chronic inhibition of cholinergic receptors by tricyclic antidepressants. Restarting the antidepressant and slow tapering is the treatment of choice for tricyclic antidepressant withdrawal. Some withdrawal symptoms may respond to anticholinergics, such as atropine or benztropine mesylate.
Sources: en.wikipedia.org
Rubin estimated that it was used to do 200 million vaccinations per year during the last years of the campaign. Those closely involved in the campaign were awarded the "Order of the Bifurcated Needle". This, a personal initiative by Donald Henderson, was a lapel badge, designed and made by his daughter, formed from the needle shaped to form an "O". This represented "Target Zero", the objective of the campaign.
== Fungi foods == Dried mushrooms – typically prepared by sun-drying, hot-air drying or freeze-drying. Some types of mushrooms that are prepared dried include shiitake, straw and morel mushrooms. Mushroom extract – a paste-like, concentrated extract made from dried edible mushrooms. Mushroom extract is used to add flavor to soups, sauces, soy sauce and other foods.
Ultraviolet helps detect organic material deposits that remain on surfaces where periodic cleaning and sanitizing may have failed. It is used in the hotel industry, manufacturing, and other industries where levels of cleanliness or contamination are inspected. Perennial news features for many television news organizations involve an investigative reporter using a similar device to reveal unsanitary conditions in hotels, public toilets, hand rails, and such.
However, dihydrotestosterone (DHT) metabolites acting as estrogen receptor beta (ERβ) agonists such as 3β-androstanediol may stimulate oxytocin production similarly to estrogens like estradiol. The entactogen MDMA, which is a serotonin–norepinephrine–dopamine releasing agent (SNDRA), strongly increases oxytocin levels in humans, by 4- to 8-fold. This appears to play a key role in the drug's entactogenic effects, including its euphoria, enhanced empathy, and reduced anxiety. Stimulants like dextroamphetamine, methamphetamine, methylphenidate, and modafinil, with are catecholamine releasing agents and/or reuptake inhibitors, do not affect oxytocin levels in humans. However, in another study, methamphetamine increased oxytocin levels during dyadic conversations, albeit to a lesser extent than MDMA. 4-Fluoroamphetamine, which shows greater serotonin release than amphetamine or methamphetamine, increases oxytocin levels in humans. The serotonin–norepinephrine releasing agent (SNRA) fenfluramine increases oxytocin levels in humans as well. Serotonergic psychedelics including LSD, psilocybin, mescaline, and dimethyltryptamine (DMT) have been found to increase oxytocin levels in humans, though with much smaller increases in levels than MDMA. The serotonin 5-HT1A receptor agonist buspirone does not affect oxytocin levels in humans, though it augmented the increase in oxytocin levels in response to hypoglycemia.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.